Erythematous Scaly Papules on the Shins and Calves

Article Type
Changed
Thu, 01/10/2019 - 13:27
Display Headline
Erythematous Scaly Papules on the Shins and Calves

The Diagnosis: Hyperkeratosis Lenticularis Perstans

A shave biopsy of a lesion on the right leg was performed. Histopathology revealed a discrete papule with overlying compact hyperkeratosis. There was parakeratosis with an absent granular layer and a lichenoid lymphocytic infiltrate within the papillary dermis (Figure). Given the clinical context, these changes were consistent with a diagnosis of hyperkeratosis lenticularis perstans (HLP), also known as Flegel disease.

Discrete papule with overlying compact hyperkeratosis and an accompanying lichenoid inflammatory infiltrate (A)(H&E, original magnification ×2). Higher power view highlighting the lichenoid inflammation and loss of the granular layer with overlying parakeratosis (B)(H&E, original magnification ×10).

The patient was started on tretinoin cream 0.1% nightly for 3 months and triamcinolone ointment 0.1% as needed for pruritus but showed no clinical response. Given the benign nature of the condition and because the lesions were asymptomatic, additional treatment options were not pursued.

Originally described by Flegel1 in 1958, HLP is a rare skin disorder commonly seen in white individuals with onset in the fourth or fifth decades of life.1,2 While most cases are sporadic,3-6 HLP also has been associated with autosomal dominant inheritance.7-10

Patients with HLP typically present with multiple 1- to 5-mm reddish-brown, hyperkeratotic, scaly papules that reveal a moist, erythematous base with pinpoint bleeding upon removal of the scale. Lesions usually are distributed symmetrically and most commonly present on the extensor surfaces of the lower legs and dorsal feet.1,2,7 Lesions also may appear on the extensor surfaces of the arms, pinna, periocular region, antecubital and popliteal fossae, and oral mucosa and also may present as pits on the palms and soles.2,4,7,8 Furthermore, unilateral and localized variants of HLP have been described.11,12 Hyperkeratosis lenticularis perstans usually is asymptomatic but can present with mild pruritus or burning.3,5,13

The etiology and pathogenesis of HLP are unknown. Exposure to UV light has been implicated as an inciting factor14; however, reports of spontaneous resolution in the summer13 and upon treatment with psoralen plus UVA therapy15 make the role of UV light unclear. Furthermore, investigators disagree as to whether the primary pathogenic event in HLP is an inflammatory process or one of abnormal keratinization.1,3,7,10 Fernandez-Flores and Manjon16 suggested HLP is an inflammatory process with periods of exacerbations and remissions after finding mounds of parakeratosis with neutrophils arranged in different strata in the stratum corneum.

Histologically, compact hyperkeratosis usually is noted, often with associated parakeratosis, epidermal atrophy with thinning or absence of the granular layer, and a bandlike lymphohistiocytic infiltrate in the papillary dermis.1-3 Histopathologic differences between recent-onset versus longstanding lesions have been found, with old lesions lacking an inflammatory infiltrate.3 Furthermore, new lesions often show abnormalities in quantity and/or morphology of membrane-coating granules, also known as Odland bodies, in keratinocytes on electron microscopy,3,10,17 while old lesions do not.3 Odland bodies are involved in normal desquamation, leading some to speculate on their role in HLP.10 Currently, it is unclear whether abnormalities in these organelles cause the retention hyperkeratosis seen in HLP or if such abnormalities are a secondary phenomenon.3,17

There are questionable associations between HLP and diabetes mellitus type 2, hyperthyroidism, basal and squamous cell carcinomas of the skin, and gastrointestinal malignancy.4,9,18 Our patient had a history of basal cell carcinoma on the face, diet-controlled diabetes mellitus, and hypothyroidism. Given the high prevalence of these diseases in the general population, however, it is difficult to ascertain whether a true association with HLP exists.

While HLP can slowly progress to involve additional body sites, it is overall a benign condition that does not require treatment. Therapeutic options are based on case reports, with no single treatment showing a consistent response. From review of the literature, therapies that have been most effective include dermabrasion, excision,19 topical 5-fluorouracil,2,17,20 and oral retinoids.8 Hyperkeratosis lenticularis perstans generally is resistant to topical steroids, retinoids, and vitamin D3 analogs, although success with betamethasone dipropionate,5 isotretinoin  
gel 0.05%,11 and calcipotriol have been reported.6 A case of HLP with clinical response to psoralen plus UVA therapy also has been described.15

References
  1. Flegel H. Hyperkeratosis lenticularis perstans. Hautarzt. 1958;9:363-364.
  2. Pearson LH, Smith JG, Chalker DK. Hyperkeratosis lenticularis perstans (Flegel’s disease). J Am Acad Dermatol. 1987;16:190-195.
  3. Ando K, Hattori H, Yamauchi Y. Histopathological differences between early and old lesions of hyperkeratosis lenticularis perstans (Flegel’s disease). Am J Dermatopathol. 2006;28:122-126.
  4. Fernández-Crehuet P, Rodríguez-Rey E, Ríos-Martín JJ, et al. Hyperkeratosis lenticularis perstans, or Flegel disease, with palmoplantar involvement. Actas Dermosifiliogr. 2009;100:157-159.
  5. Sterneberg-Vos H, van Marion AM, Frank J, et al. Hyperkeratosis lenticularis perstans (Flegel’s disease)—successful treatment with topical corticosteroids. Int J Dermatol. 2008;47:38-41.
  6. Bayramgürler D, Apaydin R, Dökmeci S, et al. Flegel’s disease: treatment with topical calcipotriol. Clin Exp Dermatol. 2002;27:161-162.
  7. Price ML, Jones EW, MacDonald DM. A clinicopathological study of Flegel’s disease (hyperkeratosis lenticularis perstans). Br J Dermatol. 1987;116:681-691.
  8. Krishnan A, Kar S. Photoletter to the editor: hyperkeratosis lenticularis perstans (Flegel’s disease) with unusual clinical presentation. response to isotretinoin therapy. J Dermatol Case Rep. 2012;6:93-95.
  9. Beveridge GW, Langlands AO. Familial hyperkeratosis lenticularis perstans associated with tumours of the skin. Br J Dermatol. 1973;88:453-458.
  10. Frenk E, Tapernoux B. Hyperkeratosis lenticularis perstans (Flegel): a biological model for keratinization occurring in the absence of Odland bodies? Dermatologica. 1976;153:253-262.
  11. Miranda-Romero A, Sánchez Sambucety P, Bajo del Pozo C, et al. Unilateral hyperkeratosis lenticularis perstans (Flegel's disease). J Am Acad Dermatol. 1998;39:655-657.
  12. Gutiérrez MC, Hasson A, Arias MD, et al. Localized hyperkeratosis lenticularis perstans (Flegel's disease). Cutis. 1991;48:201-204.
  13. Fathy S, Azadeh B. Hyperkeratosis lenticularis perstans. Int J Dermatol. 1988;27:120-121.
  14. Rosdahl I, Rosen K. Hyperkeratosis lenticularis perstans: report on two cases. Acta Derm Venerol. 1985;65:562-564.
  15. Cooper SM, George S. Flegel's disease treated with psoralen ultraviolet A. Br J Dermatol. 2000;142:340-342.
  16. Fernandez-Flores A, Manjon JA. Morphological evidence of periodical exacerbation of hyperkeratosis lenticularis perstans. Acta Dermatovenerol Croat. 2009;17:16-19.
  17. Langer K, Zonzits E, Konrad K. Hyperkeratosis lenticularis perstans (Flegel's disease). ultrastructural study of lesional and perilesional skin and therapeutic trial of topical tretinoin versus 5-fluorouracil. J Am Acad Dermatol. 1992;27:812-816.
  18. Ishibashi A, Tsuboi R, Fujita K. Familial hyperkeratosis lenticularis perstans. associated with cancers of the digestive organs. J Dermatol. 1984;11:407-409.
  19. Cunha Filho RR, Almeida Jr HL. Hyperkeratosis lenticularis perstans. An Bras Dermatol. 2011;86(4 suppl 1):S76-S77.
  20. Blaheta HJ, Metzler G, Rassner G, et al. Hyperkeratosis lenticularis perstans (Flegel's disease)—lack of response to treatment with tacalcitol and calcipotriol. Dermatology. 2001;202:255-258.
Article PDF
Author and Disclosure Information

From the University of Virginia, Charlottesville. Dr. Gosis is from the School of Medicine. Drs. Daniel and Wilson are from the Department of Dermatology. Dr. Daniel also is from the Department of Dermatopathology.

The authors report no conflict of interest.

Correspondence: Barbara B. Wilson, MD, PO Box 800718, University of Virginia Health System, Charlottesville, VA 22908 (BLW7U@hscmail.mcc.virginia.edu).

Issue
Cutis - 96(6)
Publications
Topics
Page Number
E5-E7
Legacy Keywords
hyperkeratosis lenticularis perstans;flegel's disease;Odland bodies;membrane coating granules;Keratosis;leg dermatoses;skin disease, papulosquamous;skin disease
Sections
Author and Disclosure Information

From the University of Virginia, Charlottesville. Dr. Gosis is from the School of Medicine. Drs. Daniel and Wilson are from the Department of Dermatology. Dr. Daniel also is from the Department of Dermatopathology.

The authors report no conflict of interest.

Correspondence: Barbara B. Wilson, MD, PO Box 800718, University of Virginia Health System, Charlottesville, VA 22908 (BLW7U@hscmail.mcc.virginia.edu).

Author and Disclosure Information

From the University of Virginia, Charlottesville. Dr. Gosis is from the School of Medicine. Drs. Daniel and Wilson are from the Department of Dermatology. Dr. Daniel also is from the Department of Dermatopathology.

The authors report no conflict of interest.

Correspondence: Barbara B. Wilson, MD, PO Box 800718, University of Virginia Health System, Charlottesville, VA 22908 (BLW7U@hscmail.mcc.virginia.edu).

Article PDF
Article PDF

The Diagnosis: Hyperkeratosis Lenticularis Perstans

A shave biopsy of a lesion on the right leg was performed. Histopathology revealed a discrete papule with overlying compact hyperkeratosis. There was parakeratosis with an absent granular layer and a lichenoid lymphocytic infiltrate within the papillary dermis (Figure). Given the clinical context, these changes were consistent with a diagnosis of hyperkeratosis lenticularis perstans (HLP), also known as Flegel disease.

Discrete papule with overlying compact hyperkeratosis and an accompanying lichenoid inflammatory infiltrate (A)(H&E, original magnification ×2). Higher power view highlighting the lichenoid inflammation and loss of the granular layer with overlying parakeratosis (B)(H&E, original magnification ×10).

The patient was started on tretinoin cream 0.1% nightly for 3 months and triamcinolone ointment 0.1% as needed for pruritus but showed no clinical response. Given the benign nature of the condition and because the lesions were asymptomatic, additional treatment options were not pursued.

Originally described by Flegel1 in 1958, HLP is a rare skin disorder commonly seen in white individuals with onset in the fourth or fifth decades of life.1,2 While most cases are sporadic,3-6 HLP also has been associated with autosomal dominant inheritance.7-10

Patients with HLP typically present with multiple 1- to 5-mm reddish-brown, hyperkeratotic, scaly papules that reveal a moist, erythematous base with pinpoint bleeding upon removal of the scale. Lesions usually are distributed symmetrically and most commonly present on the extensor surfaces of the lower legs and dorsal feet.1,2,7 Lesions also may appear on the extensor surfaces of the arms, pinna, periocular region, antecubital and popliteal fossae, and oral mucosa and also may present as pits on the palms and soles.2,4,7,8 Furthermore, unilateral and localized variants of HLP have been described.11,12 Hyperkeratosis lenticularis perstans usually is asymptomatic but can present with mild pruritus or burning.3,5,13

The etiology and pathogenesis of HLP are unknown. Exposure to UV light has been implicated as an inciting factor14; however, reports of spontaneous resolution in the summer13 and upon treatment with psoralen plus UVA therapy15 make the role of UV light unclear. Furthermore, investigators disagree as to whether the primary pathogenic event in HLP is an inflammatory process or one of abnormal keratinization.1,3,7,10 Fernandez-Flores and Manjon16 suggested HLP is an inflammatory process with periods of exacerbations and remissions after finding mounds of parakeratosis with neutrophils arranged in different strata in the stratum corneum.

Histologically, compact hyperkeratosis usually is noted, often with associated parakeratosis, epidermal atrophy with thinning or absence of the granular layer, and a bandlike lymphohistiocytic infiltrate in the papillary dermis.1-3 Histopathologic differences between recent-onset versus longstanding lesions have been found, with old lesions lacking an inflammatory infiltrate.3 Furthermore, new lesions often show abnormalities in quantity and/or morphology of membrane-coating granules, also known as Odland bodies, in keratinocytes on electron microscopy,3,10,17 while old lesions do not.3 Odland bodies are involved in normal desquamation, leading some to speculate on their role in HLP.10 Currently, it is unclear whether abnormalities in these organelles cause the retention hyperkeratosis seen in HLP or if such abnormalities are a secondary phenomenon.3,17

There are questionable associations between HLP and diabetes mellitus type 2, hyperthyroidism, basal and squamous cell carcinomas of the skin, and gastrointestinal malignancy.4,9,18 Our patient had a history of basal cell carcinoma on the face, diet-controlled diabetes mellitus, and hypothyroidism. Given the high prevalence of these diseases in the general population, however, it is difficult to ascertain whether a true association with HLP exists.

While HLP can slowly progress to involve additional body sites, it is overall a benign condition that does not require treatment. Therapeutic options are based on case reports, with no single treatment showing a consistent response. From review of the literature, therapies that have been most effective include dermabrasion, excision,19 topical 5-fluorouracil,2,17,20 and oral retinoids.8 Hyperkeratosis lenticularis perstans generally is resistant to topical steroids, retinoids, and vitamin D3 analogs, although success with betamethasone dipropionate,5 isotretinoin  
gel 0.05%,11 and calcipotriol have been reported.6 A case of HLP with clinical response to psoralen plus UVA therapy also has been described.15

The Diagnosis: Hyperkeratosis Lenticularis Perstans

A shave biopsy of a lesion on the right leg was performed. Histopathology revealed a discrete papule with overlying compact hyperkeratosis. There was parakeratosis with an absent granular layer and a lichenoid lymphocytic infiltrate within the papillary dermis (Figure). Given the clinical context, these changes were consistent with a diagnosis of hyperkeratosis lenticularis perstans (HLP), also known as Flegel disease.

Discrete papule with overlying compact hyperkeratosis and an accompanying lichenoid inflammatory infiltrate (A)(H&E, original magnification ×2). Higher power view highlighting the lichenoid inflammation and loss of the granular layer with overlying parakeratosis (B)(H&E, original magnification ×10).

The patient was started on tretinoin cream 0.1% nightly for 3 months and triamcinolone ointment 0.1% as needed for pruritus but showed no clinical response. Given the benign nature of the condition and because the lesions were asymptomatic, additional treatment options were not pursued.

Originally described by Flegel1 in 1958, HLP is a rare skin disorder commonly seen in white individuals with onset in the fourth or fifth decades of life.1,2 While most cases are sporadic,3-6 HLP also has been associated with autosomal dominant inheritance.7-10

Patients with HLP typically present with multiple 1- to 5-mm reddish-brown, hyperkeratotic, scaly papules that reveal a moist, erythematous base with pinpoint bleeding upon removal of the scale. Lesions usually are distributed symmetrically and most commonly present on the extensor surfaces of the lower legs and dorsal feet.1,2,7 Lesions also may appear on the extensor surfaces of the arms, pinna, periocular region, antecubital and popliteal fossae, and oral mucosa and also may present as pits on the palms and soles.2,4,7,8 Furthermore, unilateral and localized variants of HLP have been described.11,12 Hyperkeratosis lenticularis perstans usually is asymptomatic but can present with mild pruritus or burning.3,5,13

The etiology and pathogenesis of HLP are unknown. Exposure to UV light has been implicated as an inciting factor14; however, reports of spontaneous resolution in the summer13 and upon treatment with psoralen plus UVA therapy15 make the role of UV light unclear. Furthermore, investigators disagree as to whether the primary pathogenic event in HLP is an inflammatory process or one of abnormal keratinization.1,3,7,10 Fernandez-Flores and Manjon16 suggested HLP is an inflammatory process with periods of exacerbations and remissions after finding mounds of parakeratosis with neutrophils arranged in different strata in the stratum corneum.

Histologically, compact hyperkeratosis usually is noted, often with associated parakeratosis, epidermal atrophy with thinning or absence of the granular layer, and a bandlike lymphohistiocytic infiltrate in the papillary dermis.1-3 Histopathologic differences between recent-onset versus longstanding lesions have been found, with old lesions lacking an inflammatory infiltrate.3 Furthermore, new lesions often show abnormalities in quantity and/or morphology of membrane-coating granules, also known as Odland bodies, in keratinocytes on electron microscopy,3,10,17 while old lesions do not.3 Odland bodies are involved in normal desquamation, leading some to speculate on their role in HLP.10 Currently, it is unclear whether abnormalities in these organelles cause the retention hyperkeratosis seen in HLP or if such abnormalities are a secondary phenomenon.3,17

There are questionable associations between HLP and diabetes mellitus type 2, hyperthyroidism, basal and squamous cell carcinomas of the skin, and gastrointestinal malignancy.4,9,18 Our patient had a history of basal cell carcinoma on the face, diet-controlled diabetes mellitus, and hypothyroidism. Given the high prevalence of these diseases in the general population, however, it is difficult to ascertain whether a true association with HLP exists.

While HLP can slowly progress to involve additional body sites, it is overall a benign condition that does not require treatment. Therapeutic options are based on case reports, with no single treatment showing a consistent response. From review of the literature, therapies that have been most effective include dermabrasion, excision,19 topical 5-fluorouracil,2,17,20 and oral retinoids.8 Hyperkeratosis lenticularis perstans generally is resistant to topical steroids, retinoids, and vitamin D3 analogs, although success with betamethasone dipropionate,5 isotretinoin  
gel 0.05%,11 and calcipotriol have been reported.6 A case of HLP with clinical response to psoralen plus UVA therapy also has been described.15

References
  1. Flegel H. Hyperkeratosis lenticularis perstans. Hautarzt. 1958;9:363-364.
  2. Pearson LH, Smith JG, Chalker DK. Hyperkeratosis lenticularis perstans (Flegel’s disease). J Am Acad Dermatol. 1987;16:190-195.
  3. Ando K, Hattori H, Yamauchi Y. Histopathological differences between early and old lesions of hyperkeratosis lenticularis perstans (Flegel’s disease). Am J Dermatopathol. 2006;28:122-126.
  4. Fernández-Crehuet P, Rodríguez-Rey E, Ríos-Martín JJ, et al. Hyperkeratosis lenticularis perstans, or Flegel disease, with palmoplantar involvement. Actas Dermosifiliogr. 2009;100:157-159.
  5. Sterneberg-Vos H, van Marion AM, Frank J, et al. Hyperkeratosis lenticularis perstans (Flegel’s disease)—successful treatment with topical corticosteroids. Int J Dermatol. 2008;47:38-41.
  6. Bayramgürler D, Apaydin R, Dökmeci S, et al. Flegel’s disease: treatment with topical calcipotriol. Clin Exp Dermatol. 2002;27:161-162.
  7. Price ML, Jones EW, MacDonald DM. A clinicopathological study of Flegel’s disease (hyperkeratosis lenticularis perstans). Br J Dermatol. 1987;116:681-691.
  8. Krishnan A, Kar S. Photoletter to the editor: hyperkeratosis lenticularis perstans (Flegel’s disease) with unusual clinical presentation. response to isotretinoin therapy. J Dermatol Case Rep. 2012;6:93-95.
  9. Beveridge GW, Langlands AO. Familial hyperkeratosis lenticularis perstans associated with tumours of the skin. Br J Dermatol. 1973;88:453-458.
  10. Frenk E, Tapernoux B. Hyperkeratosis lenticularis perstans (Flegel): a biological model for keratinization occurring in the absence of Odland bodies? Dermatologica. 1976;153:253-262.
  11. Miranda-Romero A, Sánchez Sambucety P, Bajo del Pozo C, et al. Unilateral hyperkeratosis lenticularis perstans (Flegel's disease). J Am Acad Dermatol. 1998;39:655-657.
  12. Gutiérrez MC, Hasson A, Arias MD, et al. Localized hyperkeratosis lenticularis perstans (Flegel's disease). Cutis. 1991;48:201-204.
  13. Fathy S, Azadeh B. Hyperkeratosis lenticularis perstans. Int J Dermatol. 1988;27:120-121.
  14. Rosdahl I, Rosen K. Hyperkeratosis lenticularis perstans: report on two cases. Acta Derm Venerol. 1985;65:562-564.
  15. Cooper SM, George S. Flegel's disease treated with psoralen ultraviolet A. Br J Dermatol. 2000;142:340-342.
  16. Fernandez-Flores A, Manjon JA. Morphological evidence of periodical exacerbation of hyperkeratosis lenticularis perstans. Acta Dermatovenerol Croat. 2009;17:16-19.
  17. Langer K, Zonzits E, Konrad K. Hyperkeratosis lenticularis perstans (Flegel's disease). ultrastructural study of lesional and perilesional skin and therapeutic trial of topical tretinoin versus 5-fluorouracil. J Am Acad Dermatol. 1992;27:812-816.
  18. Ishibashi A, Tsuboi R, Fujita K. Familial hyperkeratosis lenticularis perstans. associated with cancers of the digestive organs. J Dermatol. 1984;11:407-409.
  19. Cunha Filho RR, Almeida Jr HL. Hyperkeratosis lenticularis perstans. An Bras Dermatol. 2011;86(4 suppl 1):S76-S77.
  20. Blaheta HJ, Metzler G, Rassner G, et al. Hyperkeratosis lenticularis perstans (Flegel's disease)—lack of response to treatment with tacalcitol and calcipotriol. Dermatology. 2001;202:255-258.
References
  1. Flegel H. Hyperkeratosis lenticularis perstans. Hautarzt. 1958;9:363-364.
  2. Pearson LH, Smith JG, Chalker DK. Hyperkeratosis lenticularis perstans (Flegel’s disease). J Am Acad Dermatol. 1987;16:190-195.
  3. Ando K, Hattori H, Yamauchi Y. Histopathological differences between early and old lesions of hyperkeratosis lenticularis perstans (Flegel’s disease). Am J Dermatopathol. 2006;28:122-126.
  4. Fernández-Crehuet P, Rodríguez-Rey E, Ríos-Martín JJ, et al. Hyperkeratosis lenticularis perstans, or Flegel disease, with palmoplantar involvement. Actas Dermosifiliogr. 2009;100:157-159.
  5. Sterneberg-Vos H, van Marion AM, Frank J, et al. Hyperkeratosis lenticularis perstans (Flegel’s disease)—successful treatment with topical corticosteroids. Int J Dermatol. 2008;47:38-41.
  6. Bayramgürler D, Apaydin R, Dökmeci S, et al. Flegel’s disease: treatment with topical calcipotriol. Clin Exp Dermatol. 2002;27:161-162.
  7. Price ML, Jones EW, MacDonald DM. A clinicopathological study of Flegel’s disease (hyperkeratosis lenticularis perstans). Br J Dermatol. 1987;116:681-691.
  8. Krishnan A, Kar S. Photoletter to the editor: hyperkeratosis lenticularis perstans (Flegel’s disease) with unusual clinical presentation. response to isotretinoin therapy. J Dermatol Case Rep. 2012;6:93-95.
  9. Beveridge GW, Langlands AO. Familial hyperkeratosis lenticularis perstans associated with tumours of the skin. Br J Dermatol. 1973;88:453-458.
  10. Frenk E, Tapernoux B. Hyperkeratosis lenticularis perstans (Flegel): a biological model for keratinization occurring in the absence of Odland bodies? Dermatologica. 1976;153:253-262.
  11. Miranda-Romero A, Sánchez Sambucety P, Bajo del Pozo C, et al. Unilateral hyperkeratosis lenticularis perstans (Flegel's disease). J Am Acad Dermatol. 1998;39:655-657.
  12. Gutiérrez MC, Hasson A, Arias MD, et al. Localized hyperkeratosis lenticularis perstans (Flegel's disease). Cutis. 1991;48:201-204.
  13. Fathy S, Azadeh B. Hyperkeratosis lenticularis perstans. Int J Dermatol. 1988;27:120-121.
  14. Rosdahl I, Rosen K. Hyperkeratosis lenticularis perstans: report on two cases. Acta Derm Venerol. 1985;65:562-564.
  15. Cooper SM, George S. Flegel's disease treated with psoralen ultraviolet A. Br J Dermatol. 2000;142:340-342.
  16. Fernandez-Flores A, Manjon JA. Morphological evidence of periodical exacerbation of hyperkeratosis lenticularis perstans. Acta Dermatovenerol Croat. 2009;17:16-19.
  17. Langer K, Zonzits E, Konrad K. Hyperkeratosis lenticularis perstans (Flegel's disease). ultrastructural study of lesional and perilesional skin and therapeutic trial of topical tretinoin versus 5-fluorouracil. J Am Acad Dermatol. 1992;27:812-816.
  18. Ishibashi A, Tsuboi R, Fujita K. Familial hyperkeratosis lenticularis perstans. associated with cancers of the digestive organs. J Dermatol. 1984;11:407-409.
  19. Cunha Filho RR, Almeida Jr HL. Hyperkeratosis lenticularis perstans. An Bras Dermatol. 2011;86(4 suppl 1):S76-S77.
  20. Blaheta HJ, Metzler G, Rassner G, et al. Hyperkeratosis lenticularis perstans (Flegel's disease)—lack of response to treatment with tacalcitol and calcipotriol. Dermatology. 2001;202:255-258.
Issue
Cutis - 96(6)
Issue
Cutis - 96(6)
Page Number
E5-E7
Page Number
E5-E7
Publications
Publications
Topics
Article Type
Display Headline
Erythematous Scaly Papules on the Shins and Calves
Display Headline
Erythematous Scaly Papules on the Shins and Calves
Legacy Keywords
hyperkeratosis lenticularis perstans;flegel's disease;Odland bodies;membrane coating granules;Keratosis;leg dermatoses;skin disease, papulosquamous;skin disease
Legacy Keywords
hyperkeratosis lenticularis perstans;flegel's disease;Odland bodies;membrane coating granules;Keratosis;leg dermatoses;skin disease, papulosquamous;skin disease
Sections
Questionnaire Body

A 73-year-old white woman presented to the dermatology clinic with a mildly pruritic, slowly progressive rash on the shins and calves of 10 years’ duration. She had been using triamcinolone ointment 0.1% prescribed by her primary care physician once daily for several weeks without improvement. On physical examination, multiple 1- to 4-mm erythematous, scaly papules were noted on the anterior and posterior aspects of the lower legs. No similar lesions were noted elsewhere on the body. Her medical history was remarkable for basal cell carcinoma on the face, diet-controlled diabetes mellitus, and hypothyroidism. Her family history was unremarkable.

Disallow All Ads
Alternative CME
Article PDF Media

Erythematous Scaly Patch on the Jawline

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
Erythematous Scaly Patch on the Jawline

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Three scouting punch biopsies were performed along the periphery of the lesion.
Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
Article PDF
Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD (jg3pe@virginia.edu).

Issue
Cutis - 96(4)
Publications
Topics
Page Number
E4-E6
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Sections
Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD (jg3pe@virginia.edu).

Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD (jg3pe@virginia.edu).

Article PDF
Article PDF

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Three scouting punch biopsies were performed along the periphery of the lesion.
Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Three scouting punch biopsies were performed along the periphery of the lesion.
Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
Issue
Cutis - 96(4)
Issue
Cutis - 96(4)
Page Number
E4-E6
Page Number
E4-E6
Publications
Publications
Topics
Article Type
Display Headline
Erythematous Scaly Patch on the Jawline
Display Headline
Erythematous Scaly Patch on the Jawline
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Sections
Questionnaire Body


Confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer.
Atypia of the individual melanocytes.
Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Three scouting punch biopsies were performed along the periphery of the lesion.
Confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer.
Atypia of the individual melanocytes.
Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Three scouting punch biopsies were performed along the periphery of the lesion.

A 70-year-old white woman with a history of basal cell carcinoma presented with a 
2.7×1.9-cm ill-defined, erythematous, scaly patch along the left side of the jawline. 
Ten months prior to presentation, the lesion appeared as a grayish macule that was clinically diagnosed as a pigmented actinic keratosis and was treated with cryotherapy with resolution noted at 6-month follow-up. Differential diagnosis of the current lesion included actinic keratosis, lichenoid keratosis, and superficial basal cell carcinoma. A shave biopsy was performed.

 

Disallow All Ads
Alternative CME
Article PDF Media